A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-03 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Processing === The final peptide is often modified, e.g., by glycosylation, acylation, halogenation, or hydroxylation. The responsible enzymes are usually associated to the synthetase complex and their genes are organized in the same operons or gene clusters.
The petition seeks to have the risk of serious sexual side effects persisting after discontinuation mentioned in the product labels of SSRIs and SNRIs. The lawsuit was dismissed by the United States District Court for the District of Columbia on March 25, 2025, due to the plaintiff lacking legal standing, as the court found no specific informational or physical injury. The FDA has not mandated comprehensive PSSD warnings across all SSRI and SNRI labels, though fluoxetine (Prozac) has included a warning about persistent sexual side effects since 2011. Most other SSRI and SNRI labels address sexual dysfunction during use but not explicitly after discontinuation.
On the other hand, those who feel he is vulgar (bastos) tend to be less satisfied. Despite keeping a low profile during his post-presidency, Duterte retained his popularity, topping four consecutive surveys conducted separately in March, June, September, and December 2023 by PUBLiCUS Asia on the voting disposition for 2025 Philippine Senate election.
Instances of users abusing software to generate controversial statements in the vocal style of celebrities, public officials, and other famous individuals have raised ethical concerns over voice generation AI. In response, companies such as ElevenLabs have stated that they would work on mitigating potential abuse through safeguards and identity verification. Concerns and fandoms have spawned from AI-generated music. The same software used to clone voices has been used on famous musicians' voices to create songs that mimic their voices, gaining both tremendous popularity and criticism. Similar techniques have also been used to create improved quality or full-length versions of songs that have been leaked or have yet to be released.
The structure and function of the GI tract can be described both by gross anatomy and microscopic anatomy (histology). The tract itself is divided into upper and lower tracts, and the intestines into small and large intestines.
Sources: en.wikipedia.org
The diagnostic tests of ptaquiloside inside cells include gene mutation detection, immunohistochemical detection of tumor biomarkers, chromosomal aberrations, oxidative stress for EBH, PCR, real-time PCR and DNase-SISPA (sequence-independent single primer amplification).
Open Chess Championship Peter Bacanovic (1984), Martha Stewart's stockbroker; involved in the ImClone scandal Annie Duke (1987), professional poker player Greg Giraldo (1987), stand-up comedian Anna Ivey (1994), admissions counsellor Chubby Hubby or Aun Koh (1996), Singaporean food and travel blogger Emily Drabinski (1997), librarian and educator, president of the American Library Association Tinsley Mortimer (1999), socialite and television personality Chloe Arnold (2002), Internationally acclaimed tap dancer La Carmina (2005), alternative blogger on Gothic and Japanese pop culture Alison Desir (2007), activist, runner John Cochran (2009), winner of Survivor: Caramoan Leeza Mangaldas (2011), Indian podcaster and sex educator Sara Ali Khan (2016), daughter of Indian actor, director Saif Ali Khan and actress Amrita Singh
=== 2011–2022 === KBL-BML-Unilabo Laboratory ("KBL"), based in Antwerp and the Woestyn Laboratory, based in Mouscron, January 2011 Physicians' Automated Laboratory ("PAL"), based in Bakersfield, California, US, January 2011 The laboratory business of Central Coast Pathology Consultants ("CCPC"), a high quality laboratory in California, US, February 2011 In June 2015, Sonic acquired Medisupport, based in Switzerland. In the same month, Sonic acquired KLD Laboratory, based in Belgium. In 2011, Sonic acquired the Woestyn Laboratory (Belgium), cytopathology business Labor Dr. Steinberg (Germany), Central Coast Pathology (San Luis Obispo, California), and Allied Medical and Australian Skin Cancer medical centre groups. In 2012, the company acquired Labor Oldenburg Dr. Müller (Germany) and the Western Australian pathology operations of Healthscope. In 2013, IPN acquired the Australian Locum Medical Service group and Sonic acquired Labco S.A. Group (Germany). In 2014, Sonic acquired San Pathology (Sydney). In 2015, Sonic acquired Medisupport S.A (Switzerland) and Klinisch Laboratorium Declerck (Ardooie, Belgium). In Australia, the company acquired Adelaide Pathology Partners and the Medibank Workplace Health (WPH) and Travel Doctor businesses. In 2016–2017, Sonic acquired 80% ownership of GLP systems (Hamburg, Germany). It acquired Staber Laboratory group (Munich, Germany), Medical Laboratory Bremen, and West Pacific Medical Laboratory (Los Angeles, California).
In the United States, 49 states and the District of Columbia have expanded naloxone access at a pharmacy level via standing order, protocol order, naloxone-specific collaborative practice agreement, or pharmacist prescriptive authority.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.